On March 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for 2024 and provided a business update. In preparation for the upcoming Phase 1/2 clinical trial of CYWC628 for the treatment of diabetic foot ulcers, the company recently announced the establishment of a master services agreement with Charles River Laboratories to manufacture the master cell bank, working cell bank, and fibroblast-based spheroids product. In addition, the master cell bank was completed and successfully passed all required safety testing. We anticipate the diabetic foot ulcer trial initiating in the second quarter of 2025.
